Full-time Audit & Supervisory Board Member, Rohto Pharmaceutical Co.,Ltd.
Other assets (est.): the sum of each year's after-tax income (pay + dividends in own name − estimated taxes and social insurance) dividends retained by asset-management companies (less about 20% corporate tax), and proceeds from share sales (the drop in shares from the previous year × share price, less 20.315% tax, or about 30% for asset-management companies), for the years we have data. Spending, real estate, donations and savings from earlier years are not reflected.
| Company | Held by | Shares | Stake | Price | Value | Dividends |
|---|---|---|---|---|---|---|
| Rohto Pharmaceutical Co.,Ltd. 4527 · FY ending Mar 2026 · Full-time Audit & Supervisory Board Member |
Own name | 62,000 | — | ¥2,410 | ¥149M | ¥2.9M |
| Year | Net worth | Pay | Dividends | Total income | Taxes (est.) | After tax (est.) | Share sales (after tax) |
|---|---|---|---|---|---|---|---|
| 2026 | ¥149M | ¥21.5M | ¥2.9M | ¥24.4M | ¥6.4M | ¥15.9M | — |
| 2025 | ¥138M | ¥21.0M | ¥2.2M | ¥23.2M | ¥6.1M | ¥15.1M | — |
| 2024 | ¥181M | ¥20.5M | ¥1.6M | ¥22.1M | ¥5.8M | ¥14.4M | — |
Grouped by the calendar year of each company's fiscal year-end. Years in which the person was not among the top 10 shareholders of a company exclude that company.